Mr. De la Parra is an entrepreneur focused on Information Technology, Education and Health. He is creative and results-driven and has 16+ years of Digital Strategy experience in architecture and implementation. Mr. De la Parra is the COO and Co-founding Partner at The Solomon Brokerage Firm. He currently leads as CEO at Mass Media Division & De la Parra Mobile Solutions, while also being the President of PetroM Renewable, VP of Operations & Strategy at PetroM Logistics, both divisions of PetroM Corp. Former COO & Co-founder at RegenerAge® Clinic & RegenerAge® Beauty & a member of the Board of Advisors. Former CEO & Founder at Astrum Salud Móvil and its Telemedicine service Astrum Móvil, former Digital Strategy Director & Co-founder at Dr. Jois®, BiorganicAging®, What Skin Needs™/WSN International Pty. Ltd. He also served as a member of the Board of Advisors and is former CMO at ReAnima Advanced Biosciences and former Digital Media Director at Bioquark, Inc. Within the academic and educational fields, Mr. De la Parra acted as the Executive Vice President: Executive Chairman of the WAMS Mobile Health Division, WAMS Chief Coordinating Officer, a member of the WAMS Executive Council (WAMS Executive Board), a member of the WAMS Education & Training Board (ETB), a member of the WAMS Editorial Board, an Honorary Member of the Academy Faculty FWAMS, an Honorary Fellow of the Academy & is also a Senior Partner at WAMS, The World Academy of Medical Sciences. He is also an Advisory Board member, functioned as the Chief Operating Officer and is a Co-founding Partner at The Reprogramming Medicine Association. Mr. De la Parra is also a member of the National Introducing Brokers Association and a part of the National Biofuel Board, (Alliance Program), also being the founder and former Board of Directors member of Astrum Fundación, an Advisory Board member of the Lifeboat Foundation, an Advisory Board member of the Future Worlds Center - Cyprus Neuroscience & Technology Institute (Senior TV Program), a Federated member of the International Longevity Alliance, and volunteered as Digital Strategy adviser at the Major Mouse Testing Program. He is also a member of the Web Committee at the Life Extension Advocacy Foundation / Lifespan.io and has volunteered with SENS Research Foundation for the OncoSENS Program in Digital Strategy. Alejandro De la Parra Solomon is on Google+, Facebook, and on LinkedIn.
Dr. Mahajan completed his masters in General Surgery from Marathwada University, Maharashtra and went on to pursue Diploma in Urology at the University of Vienna, Austria. In a career changing move, after three decades of being a successful general and uro-surgeon, he started his brainchild-StemRx Bioscience Solutions Pvt. Ltd. in the year 2011. This was to focus on in-depth research in the field of Regenerative Medicine and Cell Based Therapy which he believes is the solution to address the limitations of conventional therapeutic modalities. To this effect, he underwent and continues to undergo intensive training in the United States. He has devised personalized treatment protocols in cell-based therapy for more than 75 health conditions. Dr. Mahajan is a Life member and Joint Secretary of The Stem Cell Society of India as well as Vice President of Anti-Aging Foundation, Delhi and Scientific National Advisor, Indian Stem Cell Study Group. He has been appointed as Hon. Associate Professor of Regenerative Medicine and Cell Based Therapy at Dr. R N Cooper Hospital, Mumbai and Faculty for MD Transfusion Medicine at KEM Hospital, Mumbai. Examiner for various fellowship courses with D.Y. Patil Institute, Kolhapur. Dr. Mahajan’s academic collaborations include being a Member of board of studies in ITM University, Raipur / MUHS, for PhD courses, M.Sc. and Fellowship Programs in stem cells and regenerative medicine. Among his international associations, a clinical trial in collaboration with the Ohio State University, USA on Cell Based Therapy for Avascular Necrosis is noteworthy, wherein Dr. Mahajan is a Principal Investigator. He is also a principal investigator in collaboration with Indiana University, Indianapolis under the guidance of Dr Chandan Sen to conduct the first human clinical trials using TNT technology in India. His recent international ventures include extension of StemRx facilities in Africa and collaboration with an organization in Japan to launch NK cell (cancer immunotherapy) technology for solid tumours in India. His company StemRx is also working on CAR-T cells technology in India. He has published an international patent for treatment of Avascular Necrosis using Regenerative Medicine approach and Indian patents for Avascular Necrosis, Ankylosing Spondylitis, Ischemic-tolerance Mesenchymal Stem Cell treatment/technology and isolation of dental pulp stem cells. He has 13 paper publications to his credit. Dr Mahajan has also been appointed by Government of India and Government of Maharashtra as consultant and panel doctor with the director general of shipping and labour department. Dr Mahajan is also associated with scholarly Journals for reviewing articles / research publication. Some of these are • Member, Editorial Board – ASMI • Member Editorial Board for reviewing scholarly articles, Gavin Publishers • Member Health Council – Head Hunt • Expert Reviewer – Journal of Scientific Research & Report • Expert Reviewer – British Journal of Medicine & Medical Research His drive to achieve tangible outcomes in research and therapy has earned him recognition and several awards in the field of healthcare—Paris Appreciation Award and National Awards for Excellence in Healthcare (Clinical Research category) for 2 consecutive years (2016 & 2017) to name a few. Recently he has also been featured in the Forbes Healthcare magazine for his pioneering work in the field of stem cell
Sergey Suchkov, MD, Ph.D. Professor in Immunology & Medicine. Personal: Born 11 January 1957, Astrakhan, Russia.Honors: Secretary-General, United Cultural Convention, Cambridge, UK. Memberships: New York Academy of Sciences, USA; European Association for Predictive, Preventive and Personalized Medicine, Brussels; American Association for Research in Vision and Ophthalmology; International Society for Eye Research; EPMA Journal, Personalized Medicine Universe, Open J.Autoimmunity and American J.Cardiovascular Res. Editorial Boards; All-Union (from 1992 - Russian) Biochemical Society; All-Union (from 1992 - Russian) Immunological Society.
Medicine & Immunology
Frank Leu is a co-founder and CEO of Novapeutics at Philadelphia, PA - a biopharma spun-out from the University of Pennsylvania, developing a first-in-class small molecule beta-cell restoration curative for the type 2 diabetes. Prior, Frank was at a specialty pharma, Verto Institute, developing antibody therapeutics for neuroendocrine cancer. Frank holds a doctorate degree in Pharmacology from the Weill Cornell Graduate School of Medical Sciences, and performed his posdoctoral work at a Howard Hughes Medical Institute lab at the Rockefeller University. Frank also founded BioPharMatrix, an advisory firm providing pragmatic vision and intelligence in the area of lifesciences; such as working with the 1776 (formerly Benjamins Desk) on shaping, developing and running of the Pennovation Center’s biopharma laboratories at the University of Pennsylvania.
Dr. Murugan Ramalingam is Professor at the Centre for Biomaterials, Cellular & Molecular Theranostics, VIT University, India. He hss also Adjunct Professor at the Tohoku University, Japan and Professeur des Universite at the Faculté de Chirurgie Dentaire, Université de Strasbourg, France. He has worked at the WPI Advanced Institute for Materials Research, Japan, as an Assistant Professor. He has also worked at the National Institute of Standards and Technology (NIST) and the National Institutes of Health (NIH), under the U.S. National Academies Associateship program. He received his Ph.D. in Biomaterials from the CSIR-Central Leather Research Institute, University of Madras. He has also undergone training in Ethical and Policy issues on Stem Cells from Harvard University, USA, and in Operations Management from the University of Illinois-Chicago. His current research interests are focused on the development of multiphase biomedical materials, through conventional to nanotechnology to biomimetic approaches, microfabrication and bioprinting, cell patterning, stem cell differentiation, tissue engineering and drug delivery. He is the author of ~300 publications, including 20 textbooks relevant to nanotechnology, biomaterials, stem cells, tissue engineering and regenerative medicine. His current h-index is 40 with ~9400 citations. He has delivered several keynote/invited talks and has chaired/organized several international conferences related to Biomaterials, Bioprinting, Nanobiotechnology, Stem Cells and Tissue Engineering. He also serves as a board member of several international scientific and research committees in various public and private bodies and grant reviewer of various international funding agencies. He serves on the editorial boards of multiple biomaterials and tissue engineering-related journals, including the Editor-in-Chief of the Journal of Biomaterials and Tissue Engineering and the Journal of Bionanoscience. He is a recipient of several prestigious fellowships and awards, including CSIR Fellowship (India), Singapore Millennium Fellowship (SMF) (Singapore), NRC National Academies Fellowship (USA), Nationale Professeur des Universités (France), Fellow of Royal Society of Biology (UK), Fellow of Institute of Nanotechnology (UK) and Fellow of Royal Society of Chemistry (UK).
Ming Pei completed his PhD from Beijing University, China and Postdoc training from Harvard-MIT Division of Health Sciences and Technology, USA. Currently he is a tenured Professor and Director of Stem Cell and Tissue Engineering Laboratory in the Department of Orthopaedics, West Virginia University, USA. He has over 100 publications that have been cited over 3100 times, and his publication H-index is 32 and has been serving as an editorial board member of reputed Journals.
Stem cells, Tissue engineering, Biomaterials
Anne Rios obtained her PhD in 2011. Her work represented a novel cell signaling mechanism that triggers the differentiation of a defined subset of cells within a stem pool (Nature, 2011). She then joined the laboratory of Professor Visvader focusing on Breast Cancer. A researcher at the Walter and Eliza Hall Institute (WEHI) in Melbourne, she was awarded the Neil Lawrence prize at the 2016 Centenary Institute Medical Innovation Awards for her project entitled ‘A journey into the unexpected: A 3D view of breast cancer’ which represented her post-doctoral work (Nature, 2014). She has developed a new 3D imaging technique that allows scientists to visualize entire breast tissues down to a single-cell level. She is the only researcher in Australia – and one of the few in the world – to do this. In 2017, she was appointed group leader at the Princess Máxima Center and Head the Princess Máxima Imaging Centre. She is currently investigating the cellular mechanisms underlying pediatric solid tumor progression using State-of-the-art imaging technologies.